Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant antibody derivative against human CD19 and CD3

EU orphan designation number: EU/3/03/176   
Active ingredient: Recombinant antibody derivative against human CD19 and CD3
Indication: Treatment of chronic lymphocytic leukaemia
Sponsor: Amgen Europe B.V.
Minervum 7061, NL-4817 ZK Breda, Nederland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
03/12/2003 Centralised Orphan - Designation EMEA/OD/054/03 (2003)4595 of 01/12/2003
31/01/2012 Other procedure EMEA/OD/054/03
19/06/2012 Other procedure EMEA/OD/054/03
14/02/2014 Centralised Orphan - Transfer of orphan designation EMEA/OD/054/03/T/01 (2014)1030 of 12/02/2014